COHERUS ONCOLOGY INC (CHRS)
Health Care · Biotechnology / Oncology · NASDAQ
Coherus Oncology is a commercial-stage immuno-oncology company developing next-generation PD-1 inhibitors and checkpoint inhibitors for difficult-to-treat cancers including nasopharyngeal carcinoma, hepatocellular carcinoma, and head & neck squamous cell carcinoma.
What COHERUS ONCOLOGY INC does
Coherus Oncology is a fully integrated commercial-stage immuno-oncology company with an FDA-approved PD-1 inhibitor, LOQTORZI (toripalimab-tpzi), for nasopharyngeal carcinoma in the United States. The company has a pipeline of two mid-stage clinical candidates—casdozokitug (IL-27 antagonist) and tagmokitug (CCR8-targeting antibody)—designed to overcome immune resistance in cancer and intended to be developed in combination with LOQTORZI and partner agents. Coherus executes a coordinated strategy to develop new indications for LOQTORZI while advancing its pipeline through internal development and strategic partnerships globally.
Themes: immuno-oncology / checkpoint inhibitors, PD-1 inhibitors, nasopharyngeal carcinoma, hepatocellular carcinoma, head & neck squamous cell carcinoma, immune resistance / tumor microenvironment, cancer immunotherapy combinations
Fundamentals
- Price$1.42 as of 2026-08-21 close
- Market cap$219M as of 2026-08-21
- 1-year return+25.7% 2025-08-21 close $1.13 → 2026-08-21 close $1.42
- P/E1.05 as of 2026-08-24
- Net margin-259.4% as of 2026-08-24
- Gross margin+68.9% as of 2026-08-24
- ROE-183.4% as of 2026-08-24
- Debt / equity0.85 as of 2026-08-24
- Revenue growth (YoY)-64.3% as of 2026-08-24
- Beta0.97 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How CHRS compares in its sector
- price-to-earnings ratiobottom 10% 203 covered Health Care peers, as of 2026-08-24
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How COHERUS ONCOLOGY INC looks technically
COHERUS ONCOLOGY INC (CHRS) is trading 9.7% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 36 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It made a new 20-day low about 7 trading days ago. It is 45.7% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 9.7% below its 200-day average, the long-term trend line — a long-term downtrend | -9.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.41 | $1.41 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.57 | $1.57 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 1.525. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 36 trading days ago — a "death cross", a bearish long-term signal | 36 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend) | 19.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30) | 55.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($1.13 to $1.52) — its "stochastic" reading is 73 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 73.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $2.62 | $2.62 |
|---|---|---|
| From the 52-week high | it is 45.7% below its 52-week high (its highest price of the past year) | -45.7% |
| Above the 52-week low | it is 35.1% above its 52-week low (its lowest price of the past year) | +35.1% |
| Below the 52-week high | it is 45.7% below its highest point of the past year | 45.7% |
| Since a 20-day breakout | it made a new 20-day low about 7 trading days ago | 7 sessions |
| Since a 55-day breakout | it made a new 55-day low about 7 trading days ago | 7 sessions |
| All-time high | its highest closing price on record is $38.10 (set on 2015-07-22) | $38.10 |
| Given back of the 52-week move | over the past year its closes ranged ($1.07 to $2.51), and it has given back well over two thirds of its rise from last year’s low — 76% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.57 to $1.62. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 75.7% |
| From the all-time high | it is 96.3% below its all-time high | -96.3% |
| Nearest price level | it is trading 2.9% above a support level at $1.38 — a price it turned at five times since 2025-01-30, most recently on 2026-07-17. Since 2024-08-21 it has 7 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.9% |
| All-time low | its lowest closing price on record is $0.6603 (set on 2024-11-05) | $0.6603 |
| Above the all-time low | it is 115.1% above its all-time low | +115.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 86% of the past ~6 months) | 86th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.0993 between its high and its low — about 7.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.0993 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.10 and $1.56 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.10 – $1.33 – $1.56 |
| Typical daily range (% of price) | its price moves about 7.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.0% |
| Stretch from the 200-day average | it is trading 1.5 daily ranges below its 200-day average price (9.7% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.64× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 4.7% since the prior reading | +4.7% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.07 toward sell |
Candlestick patterns
1
| Since a bearish engulfing | 4 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 4 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Open gap | it gapped 9.6% above the previous close 3 sessions ago and has not traded back through the level it left behind at 1.15 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +9.6% |
| Gap filled | a 2.9% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 5.7 percentage points (the stock lost 3.4% while the market gained 2.3%) | -5.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 12.7 percentage points (the stock lost 9.6% while the market gained 3.1%) | -12.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 23.9 percentage points (the stock lost 12.9% while the market gained 11.1%) | -23.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 5.2 percentage points (the stock gained 25.7% while the market gained 20.5%) | +5.2% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 7.2% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 13.2% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -7.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 19% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $1.75 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | -18.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 10% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $1.29 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +10.5% |
Price levels it has turned at before
CHRS last closed at $1.42 on 2026-08-21. Since 2024-08-21 it has turned at 7 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.38 | Support | 2.9% below the last close | turned there five times · 2025-01-30 to 2026-07-17 |
| $1.51 | Resistance | 6.2% above the last close | turned there five times · 2024-08-29 to 2026-08-05 |
| $1.57 | Resistance | 10.7% above the last close | turned there three times · 2026-02-13 to 2026-06-22 |
| $1.26 | Support | 10.9% below the last close | turned there twice · 2025-08-25 to 2025-12-29 |
| $1.22 | Support | 13.9% below the last close | turned there four times · 2024-09-06 to 2025-09-15 |
| $1.68 | Resistance | 18.5% above the last close | turned there twice · 2025-09-19 to 2026-04-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $1.52.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $0.9587 and $1.18 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $1.52.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · Analyst price target recently RAISED · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$7.75 range $4.00 – $10.00; median $8.50
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CHRS
- Consensus EPS estimate-$0.21 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on single approved commercial product (LOQTORZI) with limited indication scope (primarily nasopharyngeal carcinoma), creating revenue concentration risk","Clinical development risk for two mid-stage pipeline candidates (casdozokitug and tagmokitug) which may fail to meet efficacy endpoints or face safety issues, delaying or preventing future revenue generation","Competition from established PD-1 inhibitors and other immune checkpoint inhibitors already approved and marketed for broader indications"]
What changed in the latest 10-Q
AI-assisted comparison of CHRS's 10-Q filed 2026-05-11 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference year changed from 2024 to 2025 in opening sentence (newer filing references year ended December 31, 2025)
- Added statement: 'On November 26, 2024, NCCN made a further update to the clinical practice guidelines for NPC to specify that LOQTORZI is the only preferred category 1 first-line treatment option...' (newer filing, November 2024 NCCN update)
- Added clinical trial information: STORM Therapeutics Phase 1b/2 study with STC-15 and LOQTORZI (clinicaltrials.gov identifier# NCT06975293)
- Added clinical supply agreement with Janssen dated February 4, 2026 regarding tagmokitug and pasritamig in metastatic castration-resistant prostate cancer Phase 1b study (newer filing only)
- Removed:
- Removed phrase 'growing revenues' from Overview section (older filing stated 'growing revenues and a pipeline')
- Removed strategy language about 'advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as through our partners, driving sales multiples and synergies from proprietary combinations' (older filing)
- Removed reference to 'lung' as a separate indication target in overview (older filing mentioned 'liver, lung, head & neck, colorectal'; newer filing states 'liver, prostate, head & neck, colorectal')
- Removed CHS-114 references using 'CHS-114' naming; replaced with 'Tagmokitug (CHS-114, formerly SRF114)' naming convention (newer filing uses proprietary name first)
- Removed phrase 'or in combination with anti-PD-1 antibodies' changed to 'in combination with anti-PD-1 antibodies' (wording change in preclinical model description)
- Removed reference to 'gastric cancer' in Phase 1b/2a study cohorts; replaced with 'upper GI adenocarcinomas' (newer filing)
- Reworded:
- Changed 'and advance the development of our two pipeline candidates in combination with LOQTORZI' to prior language about 'advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as through our partners' (strategy statement revised, newer filing simplifies to focus on pipeline candidates)
- Changed 'CHS-114 has shown anti-tumor activity as monotherapy or in combination with anti-PD-1 antibodies' to 'Tagmokitug has shown anti-tumor activity as monotherapy and in combination with anti-PD-1 antibodies' (changed 'or' to 'and')
- Changed reference from 'CHS-114' product name to 'Tagmokitug (CHS-114, formerly SRF114)' throughout (proprietary name now leads)
- Changed 'gastric cancer, esophageal squamous cell cancer and microsatellite stable (MSS) colorectal cancer' to 'upper GI adenocarcinomas, esophageal squamous cell cancer and microsatellite stable colorectal cancer' (updated cancer type terminology in Phase 1b/2a study description)
- Notes:
- The newer filing (2026-05-11) covers Q1 2026 results while older filing (2025-11-06) covers Q3 2025 results; temporal overlap is limited
- Text appears truncated at end of older filing, potentially affecting completeness of comparison for later sections
- Some changes reflect natural progression of clinical development timelines and new partnership agreements rather than substantive strategic shifts
Risk Factors
- Added:
- Newer filing (2026-05-11) adds context that the UDENYCA Sale was consummated and emphasizes its impact on future profitability and revenue replacement challenges
- Newer filing explicitly states: 'In addition, our divestiture of UDENYCA may make it more difficult or make it take more time for us to become profitable at any point in the future. UDENYCA was our largest product that contributed significantly more revenue to our business than LOQTORZI currently.'
- Newer filing adds: 'LOQTORZI may not increase its revenue contribution to our business as quickly as we project or at all and faces competition from chemotherapy and from off-label immunotherapy agents for its approved indication in nasopharyngeal carcinoma.'
- Removed:
- Older filing (2025-11-06) contains a 'Risk Factor Summary' section at the beginning that is not present in the newer filing
- Older filing's summary section includes bullet points listing principal risk factors that do not appear in the newer filing's structure
- Reworded:
- Accumulated deficit updated from $1.3 billion as of September 30, 2025 (older filing) to $1.4 billion as of March 31, 2026 (newer filing)
- Cash, cash equivalents and marketable securities updated from earlier period to $167.0 million as of March 31, 2026 (newer filing)
- Older filing states accumulated deficit 'as of September 30, 2025' while newer filing states 'as of March 31, 2026', reflecting different reporting dates
- Notes:
- The older filing text provided appears truncated at the end (cuts off mid-sentence regarding milestone payments), limiting complete comparison of all content
- Older filing includes a separate 'Risk Factor Summary' section that appears to be a structural reorganization rather than substantive content change
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for CHRS — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CHRS as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 13,424,574
- Reported value $22,687,531
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CHRS had 24,527,052 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CHRS had 15.9% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 53.59 days to cover at the same settlement.
- Reported short interest (shares) 24,527,052
- Short interest (% of shares outstanding) 15.9%
- Prior settlement (shares) 23,885,705
- Reported change 2.69%
- Days to cover (reported) 53.59
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Merck (Keytruda, PD-1 inhibitor)
- Bristol Myers Squibb (Opdivo, PD-1 inhibitor)
- Roche/Genentech (Tecentriq, PD-L1 inhibitor)
- AstraZeneca (Imfinzi, PD-L1 inhibitor)
- Regeneron (Libtayo, PD-1 inhibitor)
- Junshi Biosciences (toripalimab, co-developer)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CHRS vs…
CHRS ranks in…
Frequently asked questions
What does COHERUS ONCOLOGY INC (CHRS) do?
Coherus Oncology is a fully integrated commercial-stage immuno-oncology company with an FDA-approved PD-1 inhibitor, LOQTORZI (toripalimab-tpzi), for nasopharyngeal carcinoma in the United States. The company has a pipeline of two mid-stage clinical candidates—casdozokitug (IL-27 antagonist) and tagmokitug (CCR8-targeting antibody)—designed to overcome immune resistance in cancer and intended to be developed in combination with LOQTORZI and partner agents.
What sector is COHERUS ONCOLOGY INC (CHRS) in?
COHERUS ONCOLOGY INC (CHRS) is classified in the Health Care sector. Its industry is Biotechnology / Oncology. It trades on NASDAQ.
Who are COHERUS ONCOLOGY INC's (CHRS) competitors?
Notable peers of COHERUS ONCOLOGY INC (CHRS) include Merck (Keytruda, PD-1 inhibitor), Bristol Myers Squibb (Opdivo, PD-1 inhibitor), Roche/Genentech (Tecentriq, PD-L1 inhibitor), AstraZeneca (Imfinzi, PD-L1 inhibitor) and Regeneron (Libtayo, PD-1 inhibitor). This peer set is informational only — not financial advice.
Is COHERUS ONCOLOGY INC (CHRS) overbought or oversold right now?
COHERUS ONCOLOGY INC (CHRS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 55, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CHRS come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.